Casadevall Arturo, Focosi Daniele
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; email:
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Annu Rev Med. 2025 Jan;76(1):1-12. doi: 10.1146/annurev-med-061323-073837. Epub 2025 Jan 16.
Monoclonal antibodies (mAbs) targeting the SARS-CoV-2 Spike protein were deployed during the COVID-19 pandemic. While all of the clinically authorized mAbs were eventually defeated by SARS-CoV-2 variants, they were highly effective in preventing disease progression when given early in the course of the disease. The experience with mAbs to SARS-CoV-2 offers important lessons for the use of mAbs in future infectious disease emergencies, such as choosing mAbs that target conserved epitopes and designing cocktails to reduce the emergence of escape variants. Planning for future use must include the creation of infusion centers and the development of strategies to minimize the emergence of escape variants.
在新冠疫情期间，部署了靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的单克隆抗体（mAbs）。虽然所有临床批准的单克隆抗体最终都被SARS-CoV-2变体击败，但在疾病早期给予时，它们在预防疾病进展方面非常有效。使用针对SARS-CoV-2的单克隆抗体的经验为未来传染病紧急情况中使用单克隆抗体提供了重要教训，例如选择靶向保守表位的单克隆抗体以及设计组合疗法以减少逃逸变体的出现。未来使用的规划必须包括设立输液中心以及制定尽量减少逃逸变体出现的策略。
